During the last session, PMV Pharmaceuticals Inc. (NASDAQ:PMVP)’s traded shares were 0.57 million. At the end of the trading day, the stock’s price was $17.05, reflecting an intraday gain of 4.86% or $0.79. The 52-week high for the PMVP share is $37.04, that puts it down -117.24 from that peak though still a striking 47.27% gain since the share price plummeted to a 52-week low of $8.99. The company’s market capitalization is $820.28M, and the average intraday trading volume over the past 10 days was 0.55 million shares, and the average trade volume was 1.62 million shares over the past three months.
PMV Pharmaceuticals Inc. (PMVP) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.60. PMVP has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.41.
PMV Pharmaceuticals Inc. (NASDAQ:PMVP) trade information
PMV Pharmaceuticals Inc. (PMVP) registered a 4.86% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.86% in intraday trading to $17.05 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 14.05%, and it has moved by 5.05% in 30 days. Based on these gigs, the overall price performance for the year is -53.22%. The short interest in PMV Pharmaceuticals Inc. (NASDAQ:PMVP) is 14.34 million shares and it means that shorts have 11.25 day(s) to cover.
The consensus price target of analysts on Wall Street is $43.00, which implies an increase of 60.35% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $25.00 and $63.00 respectively. As a result, PMVP is trading at a discount of -269.5% off the target high and -46.63% off the low.
PMV Pharmaceuticals Inc. (PMVP) estimates and forecasts
Statistics show that PMV Pharmaceuticals Inc. has underperformed its competitors in share price, compared to the industry in which it operates. PMV Pharmaceuticals Inc. (PMVP) shares have gone up 14.74% during the last six months, with a year-to-date growth rate less than the industry average at -33.59% against 11.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -41.40% this quarter and then drop -30.30% in the quarter after that.
While earnings are projected to return -66.60% in 2022, the next five years will return 23.10% per annum.
PMV Pharmaceuticals Inc. is due to release its next quarterly earnings between March 01 and March 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
PMV Pharmaceuticals Inc. (NASDAQ:PMVP)’s Major holders
PMV Pharmaceuticals Inc. insiders own 7.43% of total outstanding shares while institutional holders control 133.33%, with the float percentage being 144.04%. Orbimed Advisors LLC. is the largest shareholder of the company, while 166 institutions own stock in it. As of Mar 30, 2022, the company held over 6.86 million shares (or 15.04% of all shares), a total value of $142.73 million in shares.
The next largest institutional holding, with 4.39 million shares, is of Morgan Stanley’s that is approximately 9.63% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $91.38 million.
Also, the Mutual Funds coming in first place with the largest holdings of PMV Pharmaceuticals Inc. (PMVP) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and JP Morgan Small Cap Growth Fund. Data provided on Jun 29, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 4.49 million shares. This amounts to just over 9.84 percent of the company’s overall shares, with a $63.92 million market value. The same data shows that the other fund manager holds slightly less at 0.98 million, or about 2.15% of the stock, which is worth about $20.36 million.